This is actually one of the goals in colorectal cancer - organ-sparing treatment options. In particular, using immunotherapies in the neoadjuvant, peri-operativ

This is actually one of the goals in colorectal cancer - organ-sparing treatment options. In particular, using immunotherapies in the neoadjuvant, peri-operative setting has shown tremendous benefit in colorectal cancers. Work done by Myriam Chalabi (Netherlands Cancer Institute) with the NICHE-1 study [0] and Pashtoon Kasi (Cornell) with the NEST-1 study [1] have had tremendous impacts for the up to 15% of patients who have mismatch repair deficient CRC. [0] https://ascopost.com/issues/october-25-2022/unprecedented-waterfall-plot-achieved-with-neoadjuvant-immunotherapy-in-dmmr-colon-cancer/ https://ascopost.com/issues/october-25-2022/unprecedented-wa... [1] https://www.nyp.org/advances/article/gastroenterology/ongoing-research-shows-promising-results-for-neoadjuvant-treatment-for-colorectal-cancer https://www.nyp.org/advances/article/gastroenterology/ongoin...